JP2016183182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016183182A5 JP2016183182A5 JP2016114970A JP2016114970A JP2016183182A5 JP 2016183182 A5 JP2016183182 A5 JP 2016183182A5 JP 2016114970 A JP2016114970 A JP 2016114970A JP 2016114970 A JP2016114970 A JP 2016114970A JP 2016183182 A5 JP2016183182 A5 JP 2016183182A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- antibody
- cell
- use according
- antagonistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1132408P | 2008-01-15 | 2008-01-15 | |
| US61/011,324 | 2008-01-15 | ||
| US18978608P | 2008-08-22 | 2008-08-22 | |
| US61/189,786 | 2008-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014077464A Division JP6002710B2 (ja) | 2008-01-15 | 2014-04-04 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006391A Division JP6556271B2 (ja) | 2008-01-15 | 2018-01-18 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016183182A JP2016183182A (ja) | 2016-10-20 |
| JP2016183182A5 true JP2016183182A5 (https=) | 2017-03-09 |
| JP6280161B2 JP6280161B2 (ja) | 2018-02-14 |
Family
ID=40885608
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543147A Active JP5547656B2 (ja) | 2008-01-15 | 2009-01-15 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2014077464A Active JP6002710B2 (ja) | 2008-01-15 | 2014-04-04 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2016114970A Active JP6280161B2 (ja) | 2008-01-15 | 2016-06-09 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2018006391A Active JP6556271B2 (ja) | 2008-01-15 | 2018-01-18 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2019127276A Active JP6742482B2 (ja) | 2008-01-15 | 2019-07-09 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2020126940A Active JP6960507B2 (ja) | 2008-01-15 | 2020-07-28 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2021166657A Active JP7193601B2 (ja) | 2008-01-15 | 2021-10-11 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2022196360A Active JP7412513B2 (ja) | 2008-01-15 | 2022-12-08 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2023218727A Active JP7638360B2 (ja) | 2008-01-15 | 2023-12-26 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543147A Active JP5547656B2 (ja) | 2008-01-15 | 2009-01-15 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2014077464A Active JP6002710B2 (ja) | 2008-01-15 | 2014-04-04 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006391A Active JP6556271B2 (ja) | 2008-01-15 | 2018-01-18 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2019127276A Active JP6742482B2 (ja) | 2008-01-15 | 2019-07-09 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2020126940A Active JP6960507B2 (ja) | 2008-01-15 | 2020-07-28 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2021166657A Active JP7193601B2 (ja) | 2008-01-15 | 2021-10-11 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2022196360A Active JP7412513B2 (ja) | 2008-01-15 | 2022-12-08 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2023218727A Active JP7638360B2 (ja) | 2008-01-15 | 2023-12-26 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (14) | US8562997B2 (https=) |
| EP (2) | EP2242512B1 (https=) |
| JP (9) | JP5547656B2 (https=) |
| AU (1) | AU2009205665B2 (https=) |
| CA (3) | CA3170329A1 (https=) |
| DK (3) | DK3056514T4 (https=) |
| ES (4) | ES2740823T5 (https=) |
| FI (2) | FI3056514T4 (https=) |
| PL (1) | PL4144367T3 (https=) |
| PT (3) | PT3056515T (https=) |
| WO (1) | WO2009091601A1 (https=) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070113297A1 (en) * | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| AU2009205665B2 (en) | 2008-01-15 | 2013-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| PL2995315T3 (pl) * | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| EP2477648B1 (en) | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| HRP20221260T1 (hr) * | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| CN102070719A (zh) * | 2010-11-24 | 2011-05-25 | 中国人民解放军第四军医大学 | 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47 |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| KR102338833B1 (ko) * | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| CN105121467B (zh) * | 2012-12-03 | 2019-07-05 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| ES2914814T3 (es) | 2012-12-17 | 2022-06-16 | Pf Argentum Ip Holdings Llc | Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc |
| WO2014160183A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| PT2970493T (pt) | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| CN103665165B (zh) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| NL2011904C2 (en) * | 2013-12-06 | 2015-06-09 | Stichting Vu Vumc | Leukemic stem cell markers. |
| ES3012974T3 (en) * | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| AU2015229448B2 (en) | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| US10087257B2 (en) | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| TWI759810B (zh) * | 2014-08-08 | 2022-04-01 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
| FI3656869T4 (fi) | 2014-08-26 | 2025-06-04 | Univ Leland Stanford Junior | Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| EP3209769B1 (en) * | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| EP3247464B1 (en) | 2015-01-21 | 2019-09-18 | The Board of Trustees of the Leland Stanford Junior University | Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| BR112018005322A2 (pt) | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| RU2766200C1 (ru) | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| EP3708587B1 (en) | 2015-11-27 | 2024-05-22 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
| RU2627181C2 (ru) * | 2015-12-29 | 2017-08-03 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Экспрессионный плазмидный лентивирусный вектор для гетерологичной экспрессии рекомбинантного человеческого белка cd47 |
| EP3747906A1 (en) | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| US10257847B2 (en) * | 2016-01-29 | 2019-04-09 | Qualcomm Incorporated | Small cell and communication network reconfiguration based on wireless device capabilities |
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| AU2017250029C1 (en) * | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| AU2017250809B2 (en) | 2016-04-15 | 2024-02-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| WO2017190148A1 (en) | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| KR102878970B1 (ko) | 2016-08-03 | 2025-10-30 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| EP3532497B1 (en) | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| CA3049847A1 (en) | 2017-02-24 | 2018-08-30 | Trustees Of Boston University | Isolation of human lung progenitors derived from pluripotent stem cells |
| MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
| KR20190124247A (ko) | 2017-02-27 | 2019-11-04 | 샤턱 랩스 인코포레이티드 | Csf1r-기반 키메라 단백질 |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018236904A1 (en) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF |
| SI3642242T1 (sl) | 2017-06-21 | 2024-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti |
| WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
| JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| WO2019043634A2 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
| SI4177270T1 (sl) | 2017-10-18 | 2024-10-30 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti cd47 |
| US11771764B2 (en) | 2017-11-06 | 2023-10-03 | Pfizer Inc. | CD47 blockade with radiation therapy |
| WO2019106912A1 (ja) | 2017-11-29 | 2019-06-06 | 日本電気株式会社 | 情報処理システム、情報処理方法及び記憶媒体 |
| KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| GB201720077D0 (en) * | 2017-12-01 | 2018-01-17 | Univ Oxford Innovation Ltd | Leukaemic stem cell |
| WO2019126725A1 (en) * | 2017-12-22 | 2019-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating age-related diseases |
| AU2019218271B2 (en) | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
| MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| EP3802602A1 (en) | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| JP7557920B2 (ja) | 2018-09-04 | 2024-09-30 | ファイザー・インク | 疾患治療のためのｐａｒｐ阻害と組み合わせたｃｄ４７遮断 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| CN119684457A (zh) | 2018-11-26 | 2025-03-25 | 四十七有限责任公司 | 针对c-kit的人源化抗体 |
| US20220023348A1 (en) | 2018-11-28 | 2022-01-27 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| EP3986935A4 (en) | 2019-06-19 | 2023-08-30 | Lepu Biopharma Co., Ltd. | Anti-cd47 antibodies and uses thereof |
| CN114615989A (zh) * | 2019-07-17 | 2022-06-10 | 里兰斯坦福初级大学理事会 | 用于治疗癌症的靶向整联蛋白的打结素-fc融合体与抗cd47抗体的组合 |
| JP7831937B2 (ja) | 2019-09-03 | 2026-03-17 | クリエイト・メディシンズ，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| CN114786776B (zh) | 2019-09-18 | 2026-03-24 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
| CN110755635B (zh) * | 2019-11-14 | 2022-10-11 | 天津大学 | Flu@α-cd47@RGD制剂的合成方法 |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022125439A2 (en) * | 2020-12-07 | 2022-06-16 | The Regents Of The University Of California | Innate immune cell silencing by sirp-alpha engager |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| WO2022135460A1 (zh) | 2020-12-23 | 2022-06-30 | 广东菲鹏制药股份有限公司 | 一种靶向cd47的抗体及其应用 |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022229818A1 (en) | 2021-04-27 | 2022-11-03 | Pf Argentum Ip Holdings Llc | Enhancement of cd47 blockade therapy with dhfr inhibitors |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| JP7576358B2 (ja) * | 2021-05-12 | 2024-10-31 | 国立大学法人北海道大学 | 急性骨髄性白血病の遺伝子パネル検査のためのアンプリコンｄｎａライブラリー、キット及びそれらの使用 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20240254226A1 (en) | 2021-06-10 | 2024-08-01 | Ono Pharmaceutical Co., Ltd. | Cancer treatment method by combined use of cd47 inhibitory substance, immune checkpoint inhibitory substance, and standard therapy |
| WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| US20250367255A1 (en) | 2021-11-08 | 2025-12-04 | Pfizer Inc. | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents |
| CN114262731B (zh) * | 2021-12-22 | 2024-01-23 | 上海国奥源华安生物科技有限公司 | 一种检测膀胱癌细胞用检测试剂盒及其制备方法、膀胱癌细胞的检测方法 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| CN120390653A (zh) | 2022-12-09 | 2025-07-29 | 辉瑞大药厂 | Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法 |
| WO2025088065A1 (en) * | 2023-10-25 | 2025-05-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnosis and therapy of aml |
| CN120758635B (zh) * | 2025-09-09 | 2025-12-30 | 宁波大学附属第一医院 | 急性髓系白血病的辅助诊断、预后诊断或危险度分层circRNA标记物及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1132408A (en) | 1914-06-03 | 1915-03-16 | Joseph Tabor | Train-stopping apparatus. |
| US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| JPS6280161U (https=) | 1985-11-08 | 1987-05-22 | ||
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
| WO1998016254A1 (en) * | 1996-10-17 | 1998-04-23 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
| WO1999012973A1 (en) | 1997-09-11 | 1999-03-18 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| US6491917B1 (en) * | 1998-07-31 | 2002-12-10 | Stemcell Technologies Inc. | Antibody composition for debulking blood and bone marrow samples from CML patients |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| CA2375974C (en) | 1999-06-29 | 2010-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
| DE19952960A1 (de) | 1999-11-03 | 2001-05-10 | Mark Andre Freyberg | Verfahren zur Identifizierung von anti-apoptotisch wirksamen Verbindungen |
| GB9930706D0 (en) * | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| ATE510855T1 (de) * | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
| TWI242043B (en) | 2000-03-10 | 2005-10-21 | Chugai Pharmaceutical Co Ltd | Polypeptide inducing apoptosis |
| DE10034607A1 (de) * | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| AU2002240751A1 (en) * | 2001-03-09 | 2002-09-24 | William Herman | Targeted ligands |
| CA2462653C (en) * | 2001-11-07 | 2016-06-07 | Aya Jakobovits | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-ｃｄ74 항체 및 그 이용방법 |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) * | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| JP4637749B2 (ja) * | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| CA2565907A1 (en) * | 2004-05-17 | 2005-11-24 | Crucell Holland B.V. | Methods for diagnosis of acute myeloid leukemia |
| EP1841467A4 (en) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES |
| KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| JP2007008895A (ja) | 2005-07-04 | 2007-01-18 | Chugai Pharmaceut Co Ltd | 抗ｃｄ４７抗体とインテグリンリガンドとの併用 |
| JP2005333993A (ja) * | 2005-08-03 | 2005-12-08 | Tohoku Techno Arch Co Ltd | 新規なダイアボディ型二重特異性抗体 |
| US20070113297A1 (en) * | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| US7514229B2 (en) * | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| EP2008102A4 (en) * | 2006-04-18 | 2009-07-08 | Wellstat Biologics Corp | DETECTION OF PROTEINS IN NEOPLASTIC CELLS IN CIRCULATION |
| AU2007249709A1 (en) * | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| WO2008073316A2 (en) * | 2006-12-07 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| US20100239578A1 (en) * | 2007-10-11 | 2010-09-23 | University Health Network | Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| AU2009205665B2 (en) | 2008-01-15 | 2013-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
| CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2010017332A2 (en) | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
| PL2995315T3 (pl) | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| CN101562733B (zh) * | 2009-05-20 | 2012-09-05 | 中兴通讯股份有限公司 | 将视频采集设备接入次世代网络的装置及方法 |
| EP2477648B1 (en) | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| PT2970493T (pt) | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| AU2015229448B2 (en) | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| SI3642242T1 (sl) | 2017-06-21 | 2024-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti |
-
2009
- 2009-01-15 AU AU2009205665A patent/AU2009205665B2/en active Active
- 2009-01-15 PT PT16160476T patent/PT3056515T/pt unknown
- 2009-01-15 FI FIEP16160470.7T patent/FI3056514T4/fi active
- 2009-01-15 CA CA3170329A patent/CA3170329A1/en active Pending
- 2009-01-15 DK DK16160470.7T patent/DK3056514T4/da active
- 2009-01-15 CA CA3054220A patent/CA3054220C/en active Active
- 2009-01-15 JP JP2010543147A patent/JP5547656B2/ja active Active
- 2009-01-15 FI FIEP16160476.4T patent/FI3056515T4/fi active
- 2009-01-15 DK DK16160476.4T patent/DK3056515T4/da active
- 2009-01-15 PT PT16160470T patent/PT3056514T/pt unknown
- 2009-01-15 ES ES16160476T patent/ES2740823T5/es active Active
- 2009-01-15 PT PT97019939T patent/PT2242512T/pt unknown
- 2009-01-15 EP EP09701993.9A patent/EP2242512B1/en not_active Revoked
- 2009-01-15 CA CA2711938A patent/CA2711938C/en active Active
- 2009-01-15 WO PCT/US2009/000319 patent/WO2009091601A1/en not_active Ceased
- 2009-01-15 EP EP22191294.2A patent/EP4144367B1/en active Active
- 2009-01-15 DK DK09701993.9T patent/DK2242512T3/en active
- 2009-01-15 PL PL22191294.2T patent/PL4144367T3/pl unknown
- 2009-01-15 ES ES22191294T patent/ES3060476T3/es active Active
- 2009-01-15 ES ES09701993.9T patent/ES2582340T3/es active Active
- 2009-01-15 ES ES16160470T patent/ES2735144T5/es active Active
-
2010
- 2010-07-15 US US12/837,409 patent/US8562997B2/en active Active
-
2013
- 2013-07-12 US US13/941,287 patent/US20140161825A1/en not_active Abandoned
- 2013-07-12 US US13/941,276 patent/US20140065169A1/en not_active Abandoned
-
2014
- 2014-04-04 JP JP2014077464A patent/JP6002710B2/ja active Active
-
2015
- 2015-07-14 US US14/799,328 patent/US9493575B2/en active Active
- 2015-07-15 US US14/800,474 patent/US9399682B2/en active Active
-
2016
- 2016-02-26 US US15/054,930 patent/US9611329B2/en active Active
- 2016-02-26 US US15/054,914 patent/US9605076B2/en active Active
- 2016-02-26 US US15/054,891 patent/US9624305B2/en active Active
- 2016-06-09 JP JP2016114970A patent/JP6280161B2/ja active Active
-
2017
- 2017-03-10 US US15/456,109 patent/US9765143B2/en active Active
- 2017-07-18 US US15/652,950 patent/US10640561B2/en active Active
-
2018
- 2018-01-18 JP JP2018006391A patent/JP6556271B2/ja active Active
-
2019
- 2019-03-22 US US16/361,567 patent/US20190233515A1/en not_active Abandoned
- 2019-07-09 JP JP2019127276A patent/JP6742482B2/ja active Active
-
2020
- 2020-07-28 JP JP2020126940A patent/JP6960507B2/ja active Active
-
2021
- 2021-04-07 US US17/224,722 patent/US12162939B2/en active Active
- 2021-10-11 JP JP2021166657A patent/JP7193601B2/ja active Active
-
2022
- 2022-05-04 US US17/736,896 patent/US20220267439A1/en not_active Abandoned
- 2022-12-08 JP JP2022196360A patent/JP7412513B2/ja active Active
-
2023
- 2023-12-26 JP JP2023218727A patent/JP7638360B2/ja active Active
-
2024
- 2024-11-04 US US18/936,826 patent/US20250333502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016183182A5 (https=) | ||
| JP7780481B2 (ja) | Ｂ細胞成熟抗原結合タンパク質 | |
| Sullivan-Chang et al. | Targeting CD22 in B-cell malignancies: current status and clinical outlook | |
| Glassman et al. | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy | |
| Pegram et al. | IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia | |
| CN109310764B (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| JP2020533960A (ja) | 抗ｉｌ１ｒａｐ抗体 | |
| MX2024007356A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| JP2021527431A5 (https=) | ||
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| FI3890740T3 (fi) | CD70 ja venetoklaksi, BCL-2-estäjä, yhdistelmähoito akuutin myelooisen leukemian hoitoon | |
| JP2016509582A5 (https=) | ||
| Sermer et al. | Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation | |
| MX2021010003A (es) | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. | |
| ZA202006504B (en) | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof | |
| Rasche et al. | Novel immunotherapies in multiple myeloma–chances and challenges | |
| Schlereth et al. | Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 | |
| JP2019529416A5 (https=) | ||
| PH12021552379A1 (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof | |
| IL308504A (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| Valent et al. | Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues | |
| Soleimani Samarkhazan et al. | Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens | |
| Lee et al. | Asymmetric anti-CLL-1× CD3 bispecific antibody, ABL602 2+ 1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release |